Abstract
In addition to the role in regulating leukocyte trafficking, chemokines recently have been shown to be involved in cancer growth and metastasis. Chemokine network in tumor neovascularity may be regulated by decoy receptors. Duffy antigen receptor for chemokines (DARC) is a specific decoy receptor binding with the angiogenic CC and CXC chemokines. To investigate the effects of DARC on the tumorigenesis and the metastasis potential of human breast cancer cells, human DARC cDNA was reintroduced into the MDA-MB-231 and MDA-MB-435HM cells which have a high capability of spontaneous pulmonary metastasis. We demonstrated that DARC overexpression induced inhibition of tumorigenesis and/or metastasis through interfering with the tumor angiogenesis in vivo. This inhibition is associated with decreasing CCL2 protein levels, and MVD and MMP-9 expression in xenograft tumors. In human breast cancer samples, we also demonstrated that low expression of the DARC protein is significantly associated with estrogen receptor (ER) status, MVD, lymph node metastasis, distant metastasis and poor survival. Our results suggest for the first time that DARC is a negative regulator of growth in breast cancer, mainly by sequestration of angiogenic chemokines and subsequent inhibition of tumor neovascularity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Addison CL, Belperio JA, Burdick MD, Strieter RM . (2004). BMC Cancer 4: 28.
Balkwill F . (2004). Nat Rev Cancer 4: 540–550.
Brat DJ, Bellail AC, Van Meir EG . (2005). Neuro-oncol 7: 122–133.
Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH et al. (2000). J Immunol 164: 4025–4031.
Castilho L, Rios M, Pellegrino Jr J, Saad ST, Costa FF, Reid ME . (2004). Vox Sang 87: 190–195.
Chaudhuri A, Nielsen S, Elkjaer ML, Zbrzezna V, Fang F, Pogo AO . (1997). Blood 89: 701–712.
Chaudhuri A, Yuen G, Fang F, Storry J . (2004). Br J Haematol 127: 356–359.
Chaudhuri A, Zbrzezna V, Polyakova J, Pogo AO, Hesselgesser J, Horuk R . (1994). J Biol Chem 269: 7835–7838.
Comerford I, Nibbs RJ . (2005). Immunol Lett 96: 163–174.
Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG . (1997). J Exp Med 186: 1201–1212.
Du J, Luan J, Liu H, Daniel TO, Peiper S, Chen TS et al. (2002). J Leukoc Biol 71: 141–153.
Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW et al. (2000). J Immunol 164: 3200–3206.
Horuk R, Wang ZX, Peiper SC, Hesselgesser J . (1994). J Biol Chem 269: 17730–17733.
Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD et al. (2000). Clin Cancer Res 6: 2104–2119.
Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK . (2001). J Exp Med 194: 1743–1754.
Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ . (2001). Neoplasia 3: 33–42.
Lentsch AB . (2002). FASEB J 16: 1093–1095.
Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C et al. (1997). Cell 91: 385–395.
Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ . (1993). J Biol Chem 268: 12247–12249.
Neote K, Mak JY, Kolakowski Jr LF, Schall TJ . (1994). Blood 84: 44–52.
Nibbs R, Graham G, Rot A . (2003). Semin Immunol 15: 287–294.
Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ et al. (1995). J Exp Med 181: 1311–1317.
Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K et al. (2001). Cancer 92: 1085–1091.
Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK et al. (2000). Blood 96: 34–40.
Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B et al. (2002). J Biol Chem 277: 24584–24593.
Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al. (1995). J Biol Chem 270: 27348–27357.
Szabo MC, Soo KS, Zlotnik A, Schall TJ . (1995). J Biol Chem 270: 25348–25351.
Tang T, Owen JD, Du J, Walker CL, Richmond A . (1998). DNA Seq 9: 129–143.
Tournamille C, Blancher A, Le Van Kim C, Gane P, Apoil PA, Nakamoto W et al. (2004). Immunogenetics 55: 682–694.
Tournamille C, Colin Y, Cartron JP, Le Van Kim C . (1995). Nat Genet 10: 224–228.
Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D et al. (2002). Clin Cancer Res 8: 61–74.
Vicari AP, Caux C . (2002). Cytokine Growth Factor Rev 13: 143–154.
Acknowledgements
This research was supported in part by the Outstanding Young Investigator Award of National Natural Science Foundation of China (30025015), National Key Project of China (2001BA703BO5), National Natural Science Foundation of China (30371580, 30572109, 30570695) and the Grant from Shanghai Science and Technology Committee (03J14019, 04ZR14027). We would like to thank Dr Joseph A Fontana who is from John D Dingell Veterans Affairs Medical Center, Detroit, Michigan 48201, USA to review our manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, J., Ou, ZL., Hou, YF. et al. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 25, 7201–7211 (2006). https://doi.org/10.1038/sj.onc.1209703
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209703
Keywords
This article is cited by
-
How chemokines organize the tumour microenvironment
Nature Reviews Cancer (2024)
-
Chemokine receptors differentially expressed by race category and molecular subtype in the breast cancer TCGA cohort
Scientific Reports (2022)
-
Association between ABO and Duffy blood types and circulating chemokines and cytokines
Genes & Immunity (2021)
-
Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma
Journal of Gastrointestinal Cancer (2021)
-
Oncologic Anthropology: An Interdisciplinary Approach to Understanding the Association Between Genetically Defined African Ancestry and Susceptibility for Triple Negative Breast Cancer
Current Breast Cancer Reports (2021)